Prescient Therapeutics Ltd (GREY:PSTTF)

$ 0.145 0 (0%) Market Cap: 32.90 Mil Enterprise Value: 18.46 Mil PE Ratio: 0 PB Ratio: 2.23 GF Score: 37/100

Prescient Therapeutics Ltd at TechKnow Investor Conference - Gold Coast Transcript
Aug 01, 2023
Prescient Therapeutics Ltd Webinar with Port Jackson Securities on the Company's Diversified Portfolio Presentation Transcript
Mar 29, 2023
Prescient Therapeutics Ltd Corporate Presentation Transcript
Mar 02, 2023
Prescient Therapeutics Ltd Corporate Presentation Transcript
Jan 24, 2023
Prescient Therapeutics Ltd Meeting on the Mesa Transcript
Oct 21, 2022
Prescient Therapeutics Ltd Investor Presentation Transcript
Sep 27, 2022
Prescient Therapeutics Ltd at Small Caps to discuss the company's plans for its innovative cancer therapies PTX-100 and PTX-200. Transcript
Sep 08, 2022
Prescient Therapeutics Ltd Webinar Presentation Transcript
Aug 15, 2022
Prescient Therapeutics Ltd Investor Briefing Transcript
Jun 10, 2022
Prescient Therapeutics Ltd T Small Caps to Discuss the Company's Innovative Pipeline of Personalised Cancer Therapies Transcript
Aug 12, 2021

Prescient Therapeutics Ltd Investor Briefing Transcript

Jun 10, 2022 / 02:30AM GMT

Release Date Price: $0.15

Transcript

Patrick Nelson;MD

ReachCapital Pty Ltd - CEO

/

Good afternoon everyone and welcome to Prescient Therapeutics special investor briefing on their newly unveiled cell therapy enhancement platform CellPryme. My name is Patrick Nelson, MD of reach and I'll be hosting and facilitating today's webcast but more importantly we're joined by Prescient's MD and CEO

Steven Yutomi-Clarke and Senior Vice President of Scientific Affairs Dr. Rebecca Lim. Thank you for joining us today. In today's session Steven and Rebecca will provide an overview of Prescient's new platform for enhancing cell therapies or CellPryme and how it complements their existing next-gen CAR-T platform OmniCAR.

Now to stay up to date on Prescient's news type PTX which is the code they trade on the ASX into the chat box at any time during the presentation and we'll make sure that you'll get the rest of investor updates. We expect the session to run for approximately 30 minutes and there will be a Q&A session at the very end. If you'd like to ask a question at any time, simply type it into the question box and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.